Algiax presented promising results from Phase 2 study
The study with the lead compound AP-325 shows meaningful pain reduction in patients with peripheral post-surgical neuropathic pain, with fewer side effects.
News
Tubulis’ second drug candidate enters clinical evaluation
Tubulis advances its pipeline as TUB-030, a next-generation ADC targeting advanced solid tumors, enters Phase I/IIa trial.
Tubulis enters into collaboration with Gilead Sciences
The agreement, valued at up to $415 million, combines Gilead's long-standing expertise with Tubulis' innovative technology to advance ADC treatment for solid tumors.
Thermosome presents encouraging first clinical data
Phase I Trial data show safety and potential efficacy in heavily pre-treated soft tissue sarcoma patients. In 4 out of 6 patients, the disease remained stable per RECIST.
ReCatalyst is celebrating major achievements
Our portfolio company ReCatalyst reaches significant product milestones and signs a memorandum of understanding with a Membrane Electrode Assembly producer.
Initial Investment in Lymphatica
OCCIDENT participates in the € 17.9 million Series B funding round of Lausanne-based Lymphatica Medtech that develops novel treatment options for patients …
Tubulis Receives FDA Fast Track Designation
Tubulis' TUB-040, an ADC for platinum-resistant ovarian cancer, receives FDA Fast Track, expediting its development in Phase I/IIa trials to address urgent cancer treatment needs.
Tubulis Doses First Patient in Phase I/IIa Trial for TUB-040
UB-040 targets an overexpressed antigen in ovarian and lung adenocarcinoma. The trial will enroll up to 140 patients across the US, UK, and Europe.
Avelo collaborates with global health leaders in project “BreathForDiagnosis”
The €3 million research project is funded by the European Commission under "Horizon Europe", and co-funded by the Swiss State Secretariat for Education, Research and Innovation (SERI).